by Solvay Pharmaceuticals Conference on Medicinal Chemistry, Garmisch-Partenkirchen, Germany), Kruse, C. G., (Chris G.), Timmerman, H., (Hendrick), Solvay Pharmaceuticals
fromSolvay Pharmaceuticals Conferences
by ProQuest (Firm), Solvay Pharmaceuticals Conference on Medicinal Chemistry, Garmisch-Partenkirchen, Germany), Kruse, C. G., (Chris G.), Timmerman, H., (Hendrick), Solvay Pharmaceuticals
fromSolvay Pharmaceuticals Conferences
by Solvay Pharmaceuticals Conference on Medicinal Chemistry, Garmisch-Partenkirchen, Germany), Kruse, C. G., (Chris G.), Timmerman, H., (Hendrick), Solvay Pharmaceuticals
fromSolvay Pharmaceuticals Conferences
The number of novel medications in the global industry pipeline is insufficient to suffice demand of the markets, the financial performance of several companies is declining, and sales and marketing costs are rising. This title addresses the development in synthetic and medicina…
by Solvay Pharmaceuticals Conference on Medicinal Chemistry, Garmisch-Partenkirchen, Germany), Kruse, C. G., (Chris G.), Timmerman, H., (Hendrick), Solvay Pharmaceuticals
fromSolvay Pharmaceuticals Conferences
The number of novel medications in the global industry pipeline is insufficient to suffice demand of the markets, the financial performance of several companies is declining, and sales and marketing costs are rising. This title addresses the development in synthetic and medicina…